Our single cell protection buffer, the SingleCellProtectTM

Our single cell protection buffer, the SingleCellProtectTM  was used in a recently published Nature Communication paper (doi:10.1038/s41467-017-02628-4) 3-4-2018 Previously we showed that single cells collected for genomic analysis without our protection buffer resulted in more variations and less RNA both in RNASeq and quantitative real-time PCR methods. Our specially formulated solution the SingleCellProtectTM ensures excellent quality RNA for single cell …

Recent Press release announced Hungarian companies can make a breakthrough in combating Alzheimer’s disease

The fruitful collaboration of AVIDIN Ltd. and SONEAS Research Ltd. working in the field of drug development has produced outstanding results from professional and also business point of view. AVIDIN Ltd. has dedicated to pharmaceutical research of Alzheimer’s disease from 2009. During the company’s chemical and molecular-level biological development, a novel drug candidate Q134R-K was discovered which has been patented …

Avidin’s chemistry R&D unit divided into new Divisions

Avidin’s chemistry R&D unit responsible for chemical synthesis and development was divided into two Divisions: Medicinal Chemistry Department lead by Iván Kanizsai, PhD and Organic Chemistry Department, where Árpád Balázs, PhD was appointed as the leader. Medicinal Chemistry Department is responsible for hit discovery and lead optimization supporting different drug discovery programs. Organic Chemistry Department is responsible for chemical development, …

Avidin participated in cystic fibrosis consortium meeting

Horizon 2020 Consortium meeting was held on Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters in Copenhagen, Denmark July 4-6 2017 . The meeting of the Steering Committee has included the review of the project progress, milestones and planning of actions for the next six months together with the second TAT-CF Workshop. ...

Avidin awarded with innovative, European Union grant to promote flexible work schedule

Avidin Ltd. has been funded to launch and promote the “Introducing the flexible work schedule” as part of the Economic Development and Innovation Operational Program. Funding amount: 11 789 990 Ft Funding percentage: 100% Expected end of the project: 30.06.2018. Identification number of the project: GINOP-5.3.2-16-2016-00083 Under this project the flexible work schedule is designed to better harmonize the work ...

Poster in the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Avidin is presenting a poster in collaboration with Sanders-Brown Center on Aging, University of Kentucky at the AD/PDTM 2017 meeting, the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders on Thursday, March 30, 2017. Poster: Presentation number: 138 Authors: Christopher M. Norris, Susan D. Kraner, Melanie M. Pleiss, Pradoldej Sompol, Irina A. Artiushin, Orsolya Huzian, Laszlo …

Strategic Changes in the Pipeline

Today Avidin anounced that the company has made extensive recostruction of its projects. The R&D pipeline has changed and become updated accordingly (http://avidinbiotech.com/pipeline/). Q134R, Avidin’s most advanced program has entered into Phase 1a clinical trial, and its back-up compound, QPA-2203 reaches final stages in optimization.  The C-509 program has been halted for oncology indications, while two additional drug development programs …

Approval to a Phase 1 Clinical Study

Approval to Initiate a Phase 1, First–In-Man, Clinical Study for Q134R Soneas Research Ltd. in collaboration with Avidin received approval to initiate a Phase 1, First–In-Man, clinical study for Q134R. Q134R is a potent, selective, orally available small molecule that is brain penetrant and showed good toxicity and metabolic stability profile in preclinical studies. Q134R exhibited neuroprotective and cognitive enhancing …

BIO International Convention

Meet AVIDIN in San Francisco at the BIO International Convention between  June 6-9 2016.  Our CEO and Head of International Relations are looking forward to meet you during the conference to explore possible synergies. Schedule a meeting in the parntering system.

New Product: Luciferin ethyl ester

Avidin has optimized the synthesis of  Luciferin ethyl ester, a membrane permeable analog of the primary substrate for the firefly luciferase. This reagent produces 30% higher light intensity than the parent compound. It is especially suited for sensitive detection of luciferase expressing cells in tissues and in vivo animal studies. Our solubilization buffer, provided to each ordered reagent, enables this …